Home/Pipeline/Undisclosed GLP-1RA

Undisclosed GLP-1RA

Obesity

Discovery/PreclinicalActive

Key Facts

Indication

Obesity

Phase

Discovery/Preclinical

Status

Active

Company

Maze Therapeutics

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biotech company translating human genetic insights into novel precision medicines for genetically defined diseases. Founded in 2018 and publicly traded, its core strategy leverages its proprietary Compass Platform to identify protective genetic variants as a blueprint for drug development. Key achievements include building a focused pipeline led by MZE829 for APOL1-mediated kidney disease, with promising Phase 2 proof-of-concept data recently reported, and advancing a GLP-1 agonist for obesity. The company's approach aims to de-risk drug discovery by targeting pathways with direct human genetic validation.

View full company profile

Therapeutic Areas

Renal Cardiometabolic Metabolic Disorders

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active
VIAL-INHBE (siRNA)	VIAL Dermatology CRO	Phase 1	Active